# US 12,214,103 B2 · Products for treating bleeding wounds > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,214,103 B2 - Document ID: US12214103B2 - Status: Granted - Kind: B2 - Application number: 17/416,263 - Filed: 2019-12-19 - Published: 2022-04-07 - Granted: 2025-02-04 - Earliest claimed: 2018-12-20 - Assignees: BK Giulini GmbH; FKuR Property GmbH - Applicants: Bk Giulini GmbH; FKuR PROPERTY GMBH - Inventors: Thomas Staffel; Henrike Thauern; Juergen Straub; Edmund Dolfen; Carmen Michels; Karel Krpan; Frank-Martin Neumann - Web page: https://patentgrep.com/patent/US12214103B2 ## CPC - A61L 24/001: {Use of materials characterised by their function or physical properties} - A61L 24/0084: {containing fillers of phosphorus-containing inorganic compounds, e.g. apatite} - A61L 24/0031: {Hydrogels or hydrocolloids} - A61L 2400/04: Materials for stopping bleeding - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) ## Abstract The invention relates to products in the form of pads or films for treating bleeding wounds, said products being formed from an organic polymer material that contains at least one particulate, crystalline inorganic polyphosphate finely divided in the organic polymer material, and the polyphosphate having a solubility in deionized water at 20° C. of less than 5 g/L, particularly less than 1 g/L, and the anion of the polyphosphate on average (number average) having at least four phosphorus atoms per polyphosphate anion. ## Claims ### Claim 1 An agent for use in treating bleeding wounds in mammals, in the form of a flexible sheet material formed from an organic polymer material comprising at least one particulate crystalline inorganic polyphosphate, wherein the organic polymer material forms a sheet-like continuous matrix in which the particles of the particulate crystalline inorganic polyphosphate are present in the organic polymer material in finely divided form, such that the polymer material at least partly surrounds the particles of the particulate crystalline inorganic polyphosphate distributed therein, the polyphosphate at 20° C. having a solubility in deionized water of less than 5 g/L and the anion of the polyphosphate having a number average of at least four phosphorus atoms per polyphosphate anion. ### Claim 2 (depends on 1) The agent as claimed in claim 1, wherein the polyphosphate is selected from alkali metal polyphosphates, alkaline earth metal polyphosphates, and ammonium polyphosphates. ### Claim 3 (depends on 1) The agent as claimed in claim 1, wherein the polyphosphate is a sodium polyphosphate. ### Claim 4 (depends on 1) The agent as claimed in claim 1, wherein the particles of the polyphosphate have a mass-median particle diameter, determined by static laser-light scattering, within a range from 5 to 40 μm. ### Claim 5 (depends on 1) The agent as claimed in claim 1, comprising the polyphosphate in an amount within a range from 1% to 30% by weight based on the total weight of the agent. ### Claim 6 (depends on 1) The agent as claimed in claim 1, wherein the organic polymer material is thermoplastic. ### Claim 7 (depends on 6) The agent as claimed in claim 6, wherein the organic polymer material comprises as the principal constituent, based on the organic polymers contained therein, at least one polymer selected from polyhydroxyalkanoates, polylactides, aliphatic-aromatic polyesters, aliphatic-aromatic polyamides, polyolefins, polysiloxanes, and mixtures thereof. ### Claim 8 (depends on 7) The agent as claimed in claim 7, wherein the organic polymer material comprises as the principal constituent, based on the organic polymers contained therein, i. a mixture of at least one polylactide and at least one aliphatic-aromatic polyester; or ii. at least one copolyester of a hydroxybutyric acid with a hydroxyalkanoic acid having 6 to 12 carbon atoms, or a mixture of such a copolyester with polylactide. ### Claim 9 (depends on 6) The agent as claimed in claim 6 in the form of a film. ### Claim 10 (depends on 9) The agent as claimed in claim 9, wherein the ratio of film thickness to median particle diameter of the particulate polyphosphate is within a range from 0.5:1 to 5:1. ### Claim 11 (depends on 1) The agent as claimed in claim 1, wherein the organic polymer material is in the form of a hydrogel based on an organic polymer. ### Claim 12 (depends on 11) The agent as claimed in claim 11, wherein the organic polymer material comprises as the principal constituent, based on the organic polymers contained therein, at least one hydrogel-forming polysaccharide. ### Claim 13 (depends on 11) The agent as claimed in claim 11, wherein the organic hydrogel-forming polysaccharide is a cross-linked alginate. ### Claim 14 (depends on 11) The agent as claimed in claim 11 in the form of a pad. ### Claim 15 (depends on 1) The agent as claimed in claim 1, which is packaged sterile. ### Claim 16 (depends on 1) A method for treating a mammal having a bleeding wound, comprising applying the agent of claim 1 to a wound area. ### Claim 17 (depends on 16) The method of claim 16, wherein the mammal had previously been treated with an agent that reduces blood clotting or has a coagulopathy. ### Claim 18 (depends on 1) A process for producing the agent as claimed in claim 1, comprising the incorporation of the crystalline inorganic polyphosphate and optionally further hemostatic agents into the organic polymer material, such that the polymer material at least partly surrounds the particles of the particulate crystalline inorganic polyphosphate distributed therein. ### Claim 19 (depends on 16) The method of claim 16, wherein the treating occurs during a surgical intervention. ### Claim 20 (depends on 19) The method of claim 19, wherein the surgical intervention is an operation on an internal organ.